Boston Partners raised its position in Certara, Inc. (NASDAQ:CERT – Free Report) by 36.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,298,120 shares of the company’s stock after buying an additional 614,235 shares during the quarter. Boston Partners owned about 1.51% of Certara worth $21,143,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the company. Integrated Wealth Concepts LLC purchased a new stake in shares of Certara during the second quarter worth $39,000. NorthRock Partners LLC bought a new position in shares of Certara in the second quarter worth $68,000. State of Wyoming purchased a new position in shares of Certara in the second quarter valued at $72,000. Pacer Advisors Inc. grew its position in shares of Certara by 28.1% in the first quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock valued at $75,000 after purchasing an additional 2,871 shares in the last quarter. Finally, Perigon Wealth Management LLC bought a new stake in shares of Certara during the 2nd quarter valued at $80,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.
Certara Price Performance
Shares of NASDAQ CERT opened at $10.55 on Friday. The firm has a market capitalization of $1.61 billion, a P/E ratio of -25.12 and a beta of 1.30. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.29. The stock’s 50-day simple moving average is $10.03 and its two-hundred day simple moving average is $7.45. Certara, Inc. has a twelve month low of $4.45 and a twelve month high of $12.61.
Analysts Set New Price Targets
A number of research analysts have weighed in on the company. KeyCorp lifted their target price on Certara from $9.00 to $12.00 and gave the company an “overweight” rating in a report on Friday, October 16th. UBS Group reiterated a “neutral” rating and set a $13.00 price target on shares of Certara in a research report on Friday, November 6th. Jefferies Financial Group reissued a “hold” rating and issued a $12.00 price target on shares of Certara in a report on Friday, November 6th. TD Cowen boosted their price objective on shares of Certara from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. Finally, Weiss Ratings raised shares of Certara from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, November 9th. Four equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Certara presently has an average rating of “Hold” and a consensus target price of $9.91.
Check Out Our Latest Stock Report on Certara
About Certara
Certara provides software and consulting services that support the development and use of medicines. Its biosimulation tools help pharmaceutical and biotechnology companies model how drugs behave in the body, assess potential treatment outcomes, and inform decisions during drug research and development. The company’s offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial simulation, and drug development analysis. Certara also provides scientific and regulatory consulting, including support for regulatory submissions and strategies that use modeling and simulation to guide development programs.
See Also
- Five stocks we like better than Certara
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding CERT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Certara, Inc. (NASDAQ:CERT – Free Report).
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.
